Ann: Trading Halt, page-377

So ... I am trying to join the dots here (IMHO)

In the many interviews LC has conducted, particularly around HER-Vaxx, I recall LC saying that (early on) that IMU could not to conduct Phase-3 trials because you need about $100M to do it. Also, in the last interview with ASX investor, LC said that they have not released final results of Phase-2 because patients are surviving and not dying (we don't want people to die).

So my guess is that the CR of $80M (as per AFR article) is in the ballpark on what LC mentioned it costs to fund Phase-3 trials for HER-Vaxx.

Again, this is my opinion - as always DYOR

Good luck to all long term holders !!